CYAD — Celyad Oncology SA Income Statement
0.000.00%
Last trade - 00:00
- €14.07m
- €8.12m
- €0.10m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.006 | 0.005 | 0 | 0 | 0.102 |
Cost of Revenue | |||||
Gross Profit | 0.006 | 0.005 | 0 | 0 | 0.033 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 28.9 | 17 | 26.4 | 40.9 | 8.56 |
Operating Profit | -28.9 | -17 | -26.4 | -40.9 | -8.46 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -28.6 | -17.2 | -26.5 | -40.9 | -8.51 |
Provision for Income Taxes | |||||
Net Income After Taxes | -28.6 | -17.2 | -26.5 | -40.9 | -8.45 |
Net Income Before Extraordinary Items | |||||
Net Income | -28.6 | -17.2 | -26.5 | -40.9 | -8.45 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.6 | -17.2 | -26.5 | -40.9 | -8.45 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.29 | -1.23 | -1.7 | -0.802 | -0.356 |
Dividends per Share |